"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED REGULAR APPROVAL TO CERITINIB (ZYKADIA) FOR PATIENTS WITH NSCLC WHOSE TUMORS ARE ALK-POSITIVE

FDA GRANTED REGULAR APPROVAL TO CERITINIB (ZYKADIA) FOR PATIENTS WITH NSCLC WHOSE TUMORS ARE ALK-POSITIVE

01 Jun 2017 9:57 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to ceritinib (Zykadia) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software